COMP <GO>
BRKR vs MRK // RSI-14 & 200D SMA MOMENTUM
Bruker Corporation (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: BRKR 2
— MRK 13
▲ RSI-14 & 200D SMA MOMENTUM LEADER: MRK
LAST: $57.07 (-7.95%) • MKT CAP: $9.45B
rsi-technicals
45.5
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
rsi-technicals
56.9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BRKR VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BRKR | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 45.90% | 74.80% | -28.90 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 1.30% | 20.70% | -19.40 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 75.7x | 15.3x | +60.40 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 0.46% | 3.42% | -2.96 | MRK | /fcf-yield <GO> |
| Operating Margin | 2.00% | 34.30% | -32.30 | MRK | /operating-margins <GO> |
| Net Profit Margin | -0.20% | 28.10% | -28.30 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 2.10% | 1.30% | +0.80 | BRKR | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.24% | 2.26% | -2.02 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.81 | 5.19 | -2.38 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.80% | 6.60% | +0.20 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 45.5 | 56.9 | -11.32 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.97 | 0.92 | +0.05 | BRKR | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.0x | 18.4x | +3.60 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.45B | $361.02B | -$351.57B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BRKR REV | MRK REV | BRKR GROSS % | MRK GROSS % | BRKR FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.44B | $65.01B | 45.9% | 74.8% | $43.3M | $12.36B |
| FY 2024 | $3.37B | $64.17B | 49.0% | 76.3% | $136.0M | $18.10B |
| FY 2023 | $2.96B | $60.12B | 44.0% | 44.0% | $216.7M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BRKR // BETA 0.97
MRK // BETA 0.92